CytomX Therapeutics (CTMX) Cash & Current Investments (2016 - 2025)
Historic Cash & Current Investments for CytomX Therapeutics (CTMX) over the last 12 years, with Q3 2025 value amounting to $143.6 million.
- CytomX Therapeutics' Cash & Current Investments rose 2214.34% to $143.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $143.6 million, marking a year-over-year increase of 2214.34%. This contributed to the annual value of $100.6 million for FY2024, which is 4233.94% down from last year.
- CytomX Therapeutics' Cash & Current Investments amounted to $143.6 million in Q3 2025, which was up 2214.34% from $158.1 million recorded in Q2 2025.
- In the past 5 years, CytomX Therapeutics' Cash & Current Investments ranged from a high of $393.8 million in Q1 2021 and a low of $79.9 million during Q1 2025
- Over the past 5 years, CytomX Therapeutics' median Cash & Current Investments value was $193.6 million (recorded in 2022), while the average stood at $195.9 million.
- In the last 5 years, CytomX Therapeutics' Cash & Current Investments skyrocketed by 5883.87% in 2021 and then plummeted by 4684.33% in 2025.
- CytomX Therapeutics' Cash & Current Investments (Quarter) stood at $305.2 million in 2021, then crashed by 36.56% to $193.6 million in 2022, then fell by 9.88% to $174.5 million in 2023, then plummeted by 42.34% to $100.6 million in 2024, then skyrocketed by 42.74% to $143.6 million in 2025.
- Its Cash & Current Investments was $143.6 million in Q3 2025, compared to $158.1 million in Q2 2025 and $79.9 million in Q1 2025.